Vertex Pharmaceuticals (VRTX) Non-Current Debt (2009 - 2016)
Vertex Pharmaceuticals (VRTX) posted quarterly Non-Current Debt of $74.9 million for Q2 2016, down 70.26% year-over-year from $251.9 million in Q3 2015, and down 49.91% quarter-over-quarter from $149.6 million in Q1 2016.
Vertex Pharmaceuticals (VRTX) Non-Current Debt (2009 - 2016) Analysis & Trends
Vertex Pharmaceuticals' Non-Current Debt history runs 6 years deep, the most recent figure standing at $74.9 million for Q2 2016.
- In Q2 2016, Non-Current Debt fell 70.26% year-over-year to $74.9 million; the TTM figure through Jun 2016 stood at $74.9 million (down 70.26% YoY), while the FY2015 annual figure was $223.9 million, down 20.21% from the prior year.
- Non-Current Debt for Q2 2016 stood at $74.9 million, down from $149.6 million in the prior quarter.
- The five-year high for Non-Current Debt was $294.8 million in Q3 2015, with the low at $74.9 million in Q2 2016.
- The 3-year median for Non-Current Debt is $259.1 million (2015), against an average of $229.6 million.
- The sharpest annual moves came in 2015 and 2016: Non-Current Debt climbed 0.03% in 2015, then slumped 70.26% in 2016.
- Vertex Pharmaceuticals' Non-Current Debt stood at $280.6 million in 2014, then fell by 20.21% to $223.9 million in 2015, then plunged by 66.53% to $74.9 million in 2016.
- Business Quant data shows VRTX's Non-Current Debt at $74.9 million in Q2 2016, $149.6 million in Q1 2016, and $223.9 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 74.92 Mn |
| Mar 31, 2016 | 149.57 Mn |
| Dec 31, 2015 | 223.86 Mn |
| Sep 30, 2015 | 294.83 Mn |
| Jun 30, 2015 | 251.94 Mn |
| Mar 31, 2015 | 266.27 Mn |
| Dec 31, 2014 | 280.57 Mn |
| Sep 30, 2014 | 294.74 Mn |
| Sep 30, 2011 | 105.00 Mn |
| Mar 31, 2011 | 105.00 Mn |
| Jun 30, 2010 | 117.88 Mn |
| Dec 31, 2009 | 111.31 Mn |